Table 1.
Number and percentage of cases by broad ethnic group and cancer site, England, annual average 2013–2017.
| Annual average number (%) of cases in each broad ethnic group | ||||||
|---|---|---|---|---|---|---|
| White | Asian | Black | Mixed/Multiple | Other | Not Known | |
| All cancers excluding non-melanoma skin cancer | 269,450 (89%) | 7692 (2.5%) | 5281 (1.7%) | 1225 (0.4%) | 3310 (1.1%) | 17,183 (5.6%) |
| Anal cancer | 1096 (93%) | <20 – | <20 – | <20 – | <20 – | 43 (3.7%) |
| Bladder cancer | 8077 (93%) | 123 (1.4%) | 63 (0.7%) | <20 – | 67 (0.8%) | 347 (4.0%) |
| Bone sarcoma | 393 (82%) | 36 (7.4%) | <20 – | <20 – | <20 – | 22 (4.5%) |
| Bowel cancer | 31,402 (90%) | 719 (2.1%) | 488 (1.4%) | 109 (0.3%) | 341 (1.0%) | 1744 (5.0%) |
| Brain, other CNS and intracranial tumours | 8253 (84%) | 418 (4.2%) | 197 (2.0%) | 65 (0.7%) | 171 (1.7%) | 754 (7.6%) |
| Breast cancer (females) | 39,860 (87%) | 1529 (3.3%) | 880 (1.9%) | 236 (0.5%) | 599 (1.3%) | 2612 (5.7%) |
| Breast carcinoma in situ (females) | 5641 (83%) | 299 (4.4%) | 176 (2.6%) | 40 (0.6%) | 97 (1.4%) | 518 (7.7%) |
| Cancer of unknown primary | 6360 (87%) | 131 (1.8%) | 85 (1.2%) | <20 – | 63 (0.9%) | 643 (8.8%) |
| Cervical cancer | 2280 (88%) | 66 (2.5%) | 39 (1.5%) | <20 – | 46 (1.8%) | 155 (6.0%) |
| Cervical carcinoma in situ | 15,858 (66%) | 311 (1.3%) | 244 (1.0%) | 193 (0.8%) | 246 (1.0%) | 7129 (30.0%) |
| Eye cancer | 606 (89%) | <20 – | <20 – | <20 – | <20 – | 42 (6.1%) |
| Gallbladder cancer | 728 (84%) | 53 (6.1%) | 24 (2.8%) | <20 – | <20 – | 48 (5.6%) |
| Head and neck cancer | 8677 (90%) | 336 (3.5%) | 120 (1.2%) | 40 (0.4%) | 106 (1.1%) | 388 (4.0%) |
| Hodgkin lymphoma | 1397 (80%) | 124 (7.1%) | 58 (3.3%) | 25 (1.4%) | 45 (2.6%) | 107 (6.1%) |
| Kidney cancer | 9599 (89%) | 284 (2.6%) | 183 (1.7%) | 41 (0.4%) | 117 (1.1%) | 590 (5.5%) |
| Leukaemia | 7542 (86%) | 300 (3.4%) | 149 (1.7%) | 53 (0.6%) | 122 (1.4%) | 565 (6.5%) |
| Acute lymphoblastic leukaemia | 539 (79%) | 68 (10.0%) | <20 – | <20 – | 21 (3.1%) | <20 – |
| Acute myeloid leukaemia | 2474 (89%) | 96 (3.4%) | 54 (1.9%) | <20 – | 39 (1.4%) | 106 (3.8%) |
| Chronic lymphocytic leukaemia | 2935 (86%) | 65 (1.9%) | 31 (0.9%) | <20 – | 32 (0.9%) | 335 (9.8%) |
| Chronic myeloid leukaemia | 559 (83%) | 40 (5.9%) | <20 – | <20 – | <20 – | 41 (6.1%) |
| Liver cancer | 4193 (85%) | 237 (4.8%) | 97 (2.0%) | 20 (0.4%) | 70 (1.4%) | 287 (5.9%) |
| Lung cancer | 35,304 (92%) | 612 (1.6%) | 355 (0.9%) | 99 (0.3%) | 318 (0.8%) | 1705 (4.4%) |
| Melanoma skin cancer | 12,120 (91%) | 22 (0.2%) | 22 (0.2%) | <20 – | 66 (0.5%) | 1057 (7.9%) |
| Mesothelioma | 2223 (94%) | <20 – | <20 – | <20 – | <20 – | 95 (4.0%) |
| Myeloma | 4239 (86%) | 157 (3.2%) | 223 (4.5%) | 29 (0.6%) | 62 (1.3%) | 220 (4.5%) |
| Non-Hodgkin lymphoma | 10,458 (88%) | 433 (3.6%) | 195 (1.6%) | 60 (0.5%) | 155 (1.3%) | 631 (5.3%) |
| Non-melanoma skin cancera | 98,388 (80%) | 190 (0.2%) | 93 (0.1%) | 92 (0.1%) | 457 (0.4%) | 24,537 (20.0%) |
| Oesophageal cancer | 7005 (93%) | 102 (1.4%) | 59 (0.8%) | <20 – | 47 (0.6%) | 278 (3.7%) |
| Ovarian cancer | 5449 (87%) | 222 (3.5%) | 88 (1.4%) | 29 (0.5%) | 76 (1.2%) | 404 (6.4%) |
| Pancreatic cancer | 7539 (89%) | 181 (2.1%) | 154 (1.8%) | 32 (0.4%) | 87 (1.0%) | 505 (5.9%) |
| Penile cancer | 480 (91%) | <20 – | <20 – | <20 – | <20 – | 24 (4.5%) |
| Prostate cancer | 35,782 (87%) | 732 (1.8%) | 1293 (3.1%) | 160 (0.4%) | 381 (0.9%) | 2887 (7.0%) |
| Small intestine cancer | 1208 (89%) | 42 (3.1%) | 29 (2.1%) | <20 – | <20 – | 63 (4.7%) |
| Stomach cancer | 4788 (88%) | 164 (3.0%) | 149 (2.7%) | 26 (0.5%) | 68 (1.2%) | 238 (4.4%) |
| Testicular cancer | 1633 (83%) | 73 (3.8%) | <20 – | <20 – | 43 (2.2%) | 183 (9.3%) |
| Thyroid cancer | 2352 (77%) | 273 (8.9%) | 88 (2.9%) | 29 (0.9%) | 91 (3.0%) | 223 (7.3%) |
| Uterine cancer | 6663 (86%) | 316 (4.1%) | 172 (2.2%) | 38 (0.5%) | 94 (1.2%) | 436 (5.6%) |
| Vaginal cancer | 184 (91%) | <20 – | <20 – | <20 – | <20 – | <20 – |
| Vulval cancer | 1001 (92%) | <20 – | <20 – | <20 – | <20 – | 43 (4.0%) |
| Population (millions) | ||||||
| Female Population 0–64 | 18.49 (82.4%) | 2.06 (9.2%) | 0.96 (4.3%) | 0.68 (3.0%) | 0.25 (1.1%) | N/A N/A |
| Female Population 65–90+ | 5.04 (95.1%) | 0.15 (2.9%) | 0.07 (1.3%) | 0.02 (0.4%) | 0.02 (0.3%) | N/A N/A |
| Female Population 0–90+ | 23.54 (84.8%) | 2.21 (8.0%) | 1.03 (3.7%) | 0.70 (2.5%) | 0.27 (1.0%) | N/A N/A |
| Male Population 0–64 | 18.62 (82.3%) | 2.11 (9.3%) | 0.91 (4.0%) | 0.68 (3.0%) | 0.31 (1.4%) | N/A N/A |
| Male Population 65–90+ | 4.17 (94.9%) | 0.13 (3.1%) | 0.05 (1.2%) | 0.02 (0.4%) | 0.02 (0.4%) | N/A N/A |
| Male Population 0–90+ | 22.78 (84.3%) | 2.25 (8.3%) | 0.96 (3.6%) | 0.70 (2.6%) | 0.33 (1.2%) | N/A N/A |
Case numbers and percentages not reported for sex/broad ethnic group combinations with fewer than 100 cases over the 5-year study period (e.g. annual average fewer than 20 cases).
aThere is known under-recording of NMSC so numbers may be an underestimate.